跳至主要内容
临床试验/EUCTR2022-000849-32-FI
EUCTR2022-000849-32-FI进行中(未招募)1 期

The effect of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on proximal small intestine – a potential mechanism to explain opposing effects on body weight - Tenentox

Helsinki University Hospital0 个研究点目标入组 24 人开始时间: 2022年3月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age = 18 years; HIV-positive on a stable ART including either TDF or TAF for > 6 months; HIV viral load < 200 copies for = 6 months.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 4

排除标准

  • Known or suspected enteropathies (celiac disease, inflammatory bowel disease); use of any of the following during the previous month: calcium, folic acid, iron, vitamin A, B, E supplements, pregnancy.

研究者

发起方
Helsinki University Hospital

相似试验

The effect of two related HIV-medicines (TDF and... | 临床试验